Cellectis Reports Third Quarter 2025 Financial Results and Business Update
Biotechnology company Cellectis reported its third quarter 2025 financial results, highlighting promising clinical data for its lasme-cel and eti-cel product candidates in B-ALL and NHL.
Cellectis released its third quarter 2025 financial results on November 7, 2025, alongside updates on its clinical programs. The company presented data for lasme-cel, targeting relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), and eti-cel, for relapsed/refractory non-Hodgkin lymphoma (NHL). The lasme-cel program (BALLI-01 trial) showed an overall response rate (ORR) of 68% with Process 2 and 83% at the recommended Phase 2 dose (RP2D).
The eti-cel program (NATHALI-01 trial) reported an ORR of 86% and a complete response (CR) rate of 57%. Cellectis expects a decision in the Servier arbitration by December 15, 2025. As of September 30, 2025, the company held $225 million in cash, cash equivalents, and term deposits, providing a projected runway into the second half of 2027.
"We are proud of the promising data from our core clinical product candidates," said CEO André Choulika. "Our lasme-cel program for r/r B-ALL and eti-cel program for r/r NHL demonstrated their ability to induce deep and meaningful responses, underscoring their potential to improve outcomes in diseases with high unmet medical needs."
Further updates on the NATHALI-01 trial are scheduled for presentation at the American Society of Hematology (ASH) annual meeting in 2025. The first interim analysis for the BALLI-01 trial is anticipated in the fourth quarter of 2026. Cellectis continues development of these gene-edited cell therapies.